|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Bladder Cancer | |||||
| Breast Cancer | |||||
| Melanoma (Skin) | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Breast Neoplasms | |||||
| Melanoma | |||||
| Urinary Bladder Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Breast Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Germ Cell and Embryonal | |||||
| Neoplasms, Nerve Tissue | |||||
| Neuroectodermal Tumors | |||||
| Neuroendocrine Tumors | |||||
| Nevi and Melanomas | |||||
| Skin Diseases | |||||
| Urinary Bladder Diseases | |||||
| Urogenital Neoplasms | |||||
| Urologic Diseases | |||||
| Urologic Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| decitabine | |||||
| 5 | More general drug interventions related to this trial | ||||
| Antimetabolites | |||||
| Antimetabolites, Antineoplastic | |||||
| Antineoplastic Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| Norris Comprehensive Cancer Center | |||||
| National Cancer Institute (NCI) | |||||